Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
May 31, 2026
May 31, 2026
BOSTON, Massachusetts, May 31 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
*
High-risk localized and locally advanced prostate cancer patients treated with apalutamide -a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) -plus hormone therapy before . . .
* * *
Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
*
High-risk localized and locally advanced prostate cancer patients treated with apalutamide -a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) -plus hormone therapy before . . .